SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Brander who wrote (3249)3/31/1998 10:08:00 PM
From: Dauntless  Respond to of 7041
 
Brad, thanks for the post

I guess this makes two major pharmaceutical firms that don't understand phentolamine, the FDA, the market and the physicians.

How could such knowledgeable business professionals be so mistaken.

------------------------------------------------------------------

NO ONE understands the use of phentolamine for the treatment of ED better than SGP/Zonagen. It will remain that way until the full results of all the clinical trials is revealed. All IMHO.

Thanks again.



To: Brander who wrote (3249)4/5/1998 10:37:00 PM
From: Steve H.  Read Replies (1) | Respond to of 7041
 
Did you consider that there is value to Pfizer's sales management putting Zonagen's potential entry into the marketplace as a negative incentive to it's reps.? "We'll lose market share (you'll lose sales bonuses) if we don't snap up as much as the market as possible before Vasomax gets approved any day now. Go get 'em boys!"

Creating the perception of an enemy is one of the oldest tricks of leadership.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News